Clinical Trials | September 16, 2025
Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial
Cagrilintide represents a novel approach to obesity management
Cagrilintide represents a novel approach to obesity management
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Maria Soler Nunez appointed as Chief Quality Officer
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Subscribe To Our Newsletter & Stay Updated
